Loading…
Yarrow Bioscience, Inc.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in YARW.
▼ -97.9% over 5Y.
today you would have $36.17▼ -96.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PARKPark Dental Partners, Inc. | $20.85 | — | 3.3x | — | -24.16% | $99.15M |
| MBOTMicrobot Medical Inc. | $1.48 | — | 1.4x | — | -32.91% | $99.4M |
| SEERSeer, Inc. | $1.80 | — | 0.4x | — | -26.45% | $99.67M |
| VRCAVerrica Pharmaceuticals Inc. | $5.69 |
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.
Company description provided by Yahoo Finance.
| — |
| 22.7x |
| — |
| — |
| $97.75M |
| CGTXCognition Therapeutics Inc | $1.02 | — | 2.9x | — | -83.76% | $97M |
| KLRSKalaris Therapeutics, Inc. | $4.03 | — | 1.7x | — | -79.91% | $95.93M |